Not enough buy signals with a settled T+90 horizon to measure a track record yet.
Browse the full record of transactions filed by Hindman Andrew A., Chief Financial Officer. Insider active across 1 company, notably Theravance Biopharma, Inc.. Cumulatively, 9 filings have been published. Breakdown: 0 buy · 1 sell. Total volume traded: €691k. Activity tracked since 20 May 2021. The latest transaction was disclosed on 18 November 2022 (Cession). Regulator: SEC (Form 4). All data is openly available.
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
9 of 9 declarations
Andrew A. Hindman is Senior Vice President and Chief Financial Officer at Theravance Biopharma, Inc. He is responsible for the financial management of the company, overseeing accounting and financial operations.